Cargando…
Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide
Peptide drug conjugates offer a novel strategy to achieve controlled drug release. This approach avoids the clinical obstacles of non-specific toxicity and overall drug resistance of conventional cytotoxic agents, such as paclitaxel. MMP2 plays important functions in tumour proliferation and metasta...
Autores principales: | Huang, Changjiang, Yi, Xiulin, Kong, Dexin, Chen, Ligong, Min, Gong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239547/ https://www.ncbi.nlm.nih.gov/pubmed/27447567 http://dx.doi.org/10.18632/oncotarget.10735 |
Ejemplares similares
-
Matrix metalloproteinases-2/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: preparation and in vitro and in vivo evaluation
por: Zhang, Xiaoyan, et al.
Publicado: (2016) -
New strategies for targeting matrix metalloproteinases
por: Fields, Gregg B.
Publicado: (2015) -
Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides
por: Li, Ying, et al.
Publicado: (2015) -
Matrix Metalloproteinase Inhibitor COL-3 Prevents the Development of Paclitaxel-Induced Hyperalgesia in Mice
por: Parvathy, Subramanian S., et al.
Publicado: (2012) -
Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma
por: Li, Ying, et al.
Publicado: (2016)